BridGene Biosciences Secures $28 Million in Series B+ Financing to Advance Clinical Development and Expand IMTAC™ Platform

San Jose, California, USA, October 16, 2025 – BridGene Biosciences, Inc. (“BridGene”), a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics targeting traditionally “undruggable” targets, today announced that it has recently completed a $28 million Series B+ financing round. The round was led by Bayland Capital, with participation from GTJA Investment Group, Proxima Capital, and existing investors LapamCapital and Grains Valley Capital.

The proceeds from this financing round will be primarily used to advance the clinical development of the company’s core candidate drug, BGC-515. BGC-515 is a covalent TEAD inhibitor targeting solid tumors; it is currently in Phase I clinical trials and is scheduled to initiate Phase II clinical studies in the near future. Additionally, the funds will support advancing the company’s second pipeline project into the clinical stage by 2027 and accelerate the subsequent pipeline layout in the fields of oncology and autoimmune diseases.

Meanwhile, this round of financing will further strengthen BridGene’s strategic collaboration capabilities and continue to drive the broad application potential of its independently developed IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemical proteomics platform in oncology, immunology, neuroscience, and other fields.

Dr. Ping Cao, Co-Founder and CEO of BridGene Biosciences“The financing provides the company with critical resources to accelerate the Phase II clinical development of its core asset, BGC-515. This round will not only support advancing additional pipeline projects targeting undruggable targets into clinical stages, but also help us expand the application boundaries of our IMTAC™ platform through strategic collaborations, truly translating scientific discoveries into innovative therapies that benefit patients.”

Su Yuexing, Senior Partner at Bayland Capital“We are delighted to lead this round of financing for BridGene Biosciences. BridGene’s IMTAC™ platform represents a powerful and differentiated new paradigm in drug discovery, enabling the company to develop small-molecule drugs targeting proteins long considered ‘undruggable.’ As its pipeline advances, exemplified by the covalent TEAD inhibitor BGC-515, and as multiple projects expand into therapeutic areas such as oncology and autoimmune diseases, we believe BridGene holds significant potential to deliver transformative therapies to patients and create long-term value in the biopharmaceutical industry.”

BridGene Biosciences is an innovative biotechnology company dedicated to the discovery and development of novel small-molecule drugs targeting traditionally “undruggable” targets. The company’s independently developed IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) chemical proteomics platform enables the screening of small-molecule interactions with the entire proteome in live cells, precisely identifying novel binding sites to discover candidate drug molecules with high clinical value.

Currently, BridGene boasts a diversified R&D pipeline. BGC-515, a covalent TEAD inhibitor undergoing clinical studies for solid tumors, is the company’s first candidate to enter clinical development, preliminarily validating the robust capability of its IMTAC™ platform in identifying “undruggable” targets. Leveraging this platform, the company has laid out multiple innovative projects in the fields of oncology and autoimmune diseases.

BridGene integrates chemical biology with translational medicine to continuously pioneer new therapeutic pathways, committed to delivering transformative innovative therapies to patients worldwide.

Established in 2019, Kangjun Investment Management (Beijing) Co., Ltd. is a professional private equity investment management firm. As the sole global investment platform of Pharmaron, Bayland Capital leverages Pharmaron’s robust industrial background to focus on equity investments in the biopharmaceutical sector. With a unique industry perspective, Bayland Capital targets globally leading new drug R&D services and technology innovation platforms, biotechnology companies, and medical device companies, striving to become a trusted long-term partner and a vital link connecting life sciences, the health industry, and capital.

Established in Shenzhen in 2001, GTJA Investment Group pioneered the "themed industry investment" model within the sector. Focusing on investments in the healthcare and medical industry, the firm employs strategic equity investment as its core approach, covering all stages of investment including VC, PE, Pre-IPO, and M&A. Boasting one of the few professional investment teams in China with a deep focus on the healthcare track, GTJA is committed to becoming a globally influential healthcare investment institution. With assets under management exceeding RMB 23 billion, the firm has invested in more than 110 healthcare companies and facilitated the successful IPOs of 41 enterprises, including Mindray Medical, United Imaging Healthcare, and Akeso Biopharma. With its business rooted in China and oriented towards the world, GTJA has established operational centers in Shenzhen, Shanghai, Beijing, Hong Kong, and other locations. It is dedicated to investing in outstanding healthcare companies globally, creating new development opportunities for global capital and medical enterprises, and assisting entrepreneurs in building great companies.

Proxima Capital is a leading medical technology investment firm in China, managing multiple RMB and USD funds with a focus on driving breakthrough innovations that hold global commercial value. To date, Proxima has invested in over 70 companies and spearheaded the establishment of more than 30 platform companies, covering high-end medical devices, biotechnology, and life sciences. The portfolio has achieved over 60 global first-in-class product breakthroughs, secured more than 40 international certifications, and completed global market deployment for over 80% of its products. Adhering to its core strategy of “comprehensive empowerment + strategic integration,” Proxima builds an internationally leading innovation ecosystem and continuously sets benchmarks for the global value of China’s healthcare industry.

Since its inception in 2012, Grains Valley Capital has focused on early-stage venture capital investments in frontier technologies, including information technology, life sciences, artificial intelligence, and clean technology. The firm currently manages assets exceeding RMB 3 billion and has cumulatively invested in more than 50 companies, such as Hello TransTech and Unisound. Adhering to the core principles of in-depth industry research and long-term collaboration, our vision is to empower the exploration of new frontiers of human civilization.